BONE METABOLIC DETERMINANTS OF THE EFFICACY OF ZOMETA IN PATIENTS WITH DISSEMINATED PROSTATE CANCER
The efficacy of Zometa has been evaluated in the treatment of patients with disseminated prostate cancer. The use of Zometa as an inhibitor of bone resorption in the presence moderate changes in the activity of bone resorptive processes has shown the highest survival rates.
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-08-01
|
| Series: | Onkourologiâ |
| Subjects: | |
| Online Access: | https://oncourology.abvpress.ru/oncur/article/view/262 |